Haloperidol
Also known as: HALO
Use
Haloperidol testing is used to monitor therapeutic drug levels and ensure optimal drug therapy. It helps in determining patient adherence to prescribed medication regimens and adjusting dosages for therapeutic effectiveness. Monitoring is crucial for preventing adverse effects such as drowsiness, blurred vision, and motor coordination issues.
Special Instructions
Timing of specimen collection should be a pre-dose (trough) draw at steady state concentration. Collect serum or plasma using specific tubes and separate within two hours. Avoid gel separator tubes, whole blood, and specific anticoagulant tubes as these are deemed unacceptable for the test.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration but is conducted in a CLIA-certified laboratory for clinical purposes. Results of the test should be considered in conjunction with the clinical picture and other diagnostic assessments, as there may be variations in individual responses to haloperidol therapy.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 3669-9
Result Turnaround Time
1-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to the transport tube.
Patient Preparation
Pre-dose (trough) draw at steady state concentration.
Storage Instructions
Refrigerated.
Causes for Rejection
Whole blood and gel separator tubes are unacceptable conditions.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |